首页> 外文期刊>The journal of clinical endocrinology and metabolism >Prevalence of Growth Hormone Deficiency in Hashimoto’s Thyroiditis
【24h】

Prevalence of Growth Hormone Deficiency in Hashimoto’s Thyroiditis

机译:Hashimoto甲状腺炎生长激素缺乏的患病率

获取原文
       

摘要

Context: Autoimmune hypophysitis can result in GH deficiency (GHD) and is associated with other autoimmune endocrine diseases like Hashimoto’s thyroiditis. Recent studies suggest a high prevalence (5%) of GHD in Hashimoto’s thyroiditis.Objective: Our objective was to establish the prevalence of GHD in patients with treated autoimmune hypothyroidism (AIH).Patients: We included patients with spontaneous AIH [thyroid peroxidase antibodies (TPO-Ab) ≥100 kU/liter], who were adequately treated with T_(4) (TSH 0.2–5.0 mU/liter). Exclusion criteria were previous I~(131) treatment, thyroid surgery, or a history of hypothalamic or pituitary disease. Patients were recruited via our outpatient clinics and via patient self-help organizations.Design: We measured serum TSH, free T_(4), TPO-Ab, and IGF-I. If the IGF-I concentration was below the 10th percentile of age-specific reference values, a GHRH/GH-releasing peptide (GHRP)-6 test was done. GHD was defined as a GH peak after GHRH/GHRP-6 below the 2.5th percentile of age-specific reference values.Main Outcome Measures: IGF-I concentration and GH peak after GHRH/GHRP-6 test were measured.Results: From 860 patients who applied, 322 did not satisfy inclusion criteria (157 because TPO-Ab was <100 kU/liter, 165 because TSH was 5.0 mU/liter), and 23 had an exclusion criterion. In the remaining study population of 515 patients (476 female, 39 male), 49 patients (9.5%) had an IGF-I concentration below the 10th percentile. These patients underwent a GHRH/GHRP-6 test. Two patients had a GH peak below the 2.5th percentile.Conclusion: The prevalence of GHD in Dutch patients with AIH is 0.4% (two of 515).
机译:背景:自身免疫性衰弱性可能导致GH缺乏(GHD),并且与其他自身免疫内分泌疾病如散列瘤的甲状腺炎有关。最近的研究表明Hashimoto的甲状腺炎的GHD患病率高(5%)。目的是在治疗自身免疫甲状腺功能减退症(AIH)的患者中建立了GHD的患病率.Patiants:我们包括自发AIH患者[甲状腺过氧化物酶抗体( TPO-AB)≥100KU/升],用T_(4)充分治疗(TSH 0.2-5.0 mu /升)。排除标准以前是I〜(131)治疗,甲状腺手术,或下丘脑或脑垂疾病的历史。通过我们的门诊诊所和患者自助组织招募患者.Design:我们测量血清TSH,免费T_(4),TPO-AB和IGF-I。如果IGF-1浓度低于年龄特异性参考值的第10百分位,则完成GHRH / GH释放肽(GHRP)-6试验。 GHD被定义为GHRH / GHRP-6之后的GH峰值,低于年龄特异性参考值的2.5百分位数.MAIN结果措施:GHRH / GHRP-6测试后IGF-I浓度和GH峰值。结果:来自860应用的患者322不满足纳入标准(157,因为TPO-AB是<100 ku /升,因为TSH为5.0 mu /升),23次排除标准。在515名患者(476名女性,39名男性)的剩余学习人群中,49名患者(9.5%)的IGF-1浓度低于10百分位数。这些患者经历了GHRH / GHRP-6测试。两名患者的GH峰值低于2.5百分位数。结论:荷兰AIH患者的GHD患病率为0.4%(515分中的两个)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号